7 recruiting, 2 completed, 1 enrolling by invitation, 1 unknown. 4 Phase 1, 3 Not applicable, 1 Early Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Recruiting 4 |
| Not applicable | 3 | Recruiting 2, Completed 1 |
| Early Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Unknown 1 |
| Phase 3 | 1 | Enrolling by invitation 1 |
Follow SCC - Squamous Cell Carcinoma: new trials by email Literature Review of SCC - Squamous Cell Carcinoma trials Research Report on SCC - Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC) Nivolumab-IRDye800 - HNSCC, SCC - Squamous Cell Carcinoma | Early Phase 1 | Recruiting | Vanderbilt-Ingram Cancer Center | 18 | 2026-09-30 | 2026-10-19 |
| Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma Cetuximab (EGFR inhibitor), 18F-NOTA-ABY-030, Positron Emission Tomography (PET) - SCC - Squamous Cell Carcinoma, Radiotracer | Phase 1 | Recruiting | Vanderbilt-Ingram Cancer Center | 25 | 2026-04-24 | 2026-05-11 |
| Investigation of Effect of Formulated Methylene Blue on Treatment of Squamous Cell Carcinoma Skin Cancer in Inoperable Patients and Not Suitable for Radiotherapy Formulated Topical Methylene Blue (0.5 mg/mL), Wound Healing Gel - SCC - Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma of Skin | Phase 3 | Enrolling by invitation | Daryoush Hamidi Alamdari, PhD | 20 | 2025-12-20 | 2026-01-06 |
| High-Resolution PET-CT Imaging for Surgical Margin Visualization Intra-op PET/CT Specimen Scanner - Cancer, Solid Malignant Tumors | Not applicable | Recruiting | Vanderbilt-Ingram Cancer Center | 50 | 2025-09-03 | 2026-05-08 |
| Effectiveness and Safety of X A-DERM™ Microsurfaced Acellular Dermal Matrix for Wound Healing After MOHS Surgery A microsurfaced ADM (acellular dermal matrix) - Wound Healing After MMS Surgery, BCC - Basal Cell Carcinoma | Not applicable | Completed | McGuire Institute | 16 | 2025-08-08 | 2026-04-24 |
| Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer VRP-encapsulated saRNA encoding IL-12 (1 x 10^9 viral particles per injection), Pembrolizumab (KEYTRUDA®), VRP-encapsulated saRNA encoding IL-12 (3 x 10^8 viral particles per injection) - Head and Neck Cancers- Squamous Cell, Head and Neck Cancer | Phase 1 | Recruiting | VLP Therapeutics | 41 | 2025-05-13 | 2026-09-21 |
| Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer Panitumumab IRDye 800 - HNSCC, HNSCC,Larynx, Pharynx and Oral Cavity | Phase 1 | Recruiting | Vanderbilt-Ingram Cancer Center | 70 | 2025-04-17 | 2026-08-03 |
| Prognostic Value of Measuring CtDNA in a Cohort of Patients With Stage III and IV Upper Aero-digestive Tract (UADT) Cancer , Treated With Curative RADiOtherapy With or Without Concomitant Treatment. Blood samples - SCC - Squamous Cell Carcinoma, Upper Aero-digestive Tract (UADT) Neoplasm | Not applicable | Recruiting | Institut de Cancérologie de Lorraine | 188 | 2024-09-30 | 2025-12-24 |
| A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer MQ719, Pembrolizumab - Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 56 | 2023-05-04 | 2026-08-12 |
| L19IL2/L19TNF in Skin Cancer Patients L19IL2/L19TNF - BCC - Basal Cell Carcinoma, SCC - Squamous Cell Carcinoma | Phase 2 | Unknown | Philogen S.p.A. | 70 | 2023-03-09 | 2023-10-06 |
| Serum Lipid Profile and Lip Squamous Cell Carcinoma Lipid Profile, Lipids | Completed | Akdeniz University | 56 | 2018-01-01 | 2025-06-06 |
Carcinoma, Squamous Cell (11) · Squamous Cell Carcinoma of Head and Neck (6) · Head and Neck Neoplasms (5) · Mouth Neoplasms (5) · Neoplasms (4) · Carcinoma, Basal Cell (3) · Carcinoma, Merkel Cell (2) · Laryngeal Diseases (2) · Sarcoma, Kaposi (2) · Tongue Neoplasms (2) · Adenocarcinoma, Sebaceous (1) · Carcinoma (1) · Carcinoma, Skin Appendage (1) · Hemangiosarcoma (1) · Lip Neoplasms (1)
Neoplasms by Histologic Type (11) · Neoplasms, Glandular and Epithelial (11) · Neoplasms, Squamous Cell (11) · Carcinoma (10) · Neoplasms by Site (8) · Neoplasms (7) · Mouth Diseases (5) · Stomatognathic Diseases (5) · Head and Neck Neoplasms (3) · Neoplasms, Basal Cell (3) · Adenocarcinoma (2) · Carcinoma, Neuroendocrine (2) · DNA Virus Infections (2) · Herpesviridae Infections (2) · Infections (2)
pembrolizumab (2) · Blood Specimen Collection (1) · Cetuximab (1) · Magnetic Resonance Spectroscopy (1) · daromun (1)
Vanderbilt-Ingram Cancer Center (4) · Akdeniz University (1) · Daryoush Hamidi Alamdari, PhD (1) · Institut de Cancérologie de Lorraine (1) · McGuire Institute (1) · Memorial Sloan Kettering Cancer Center (1) · Philogen S.p.A. (1) · VLP Therapeutics (1)
United States (7) · France (2) · Iran (1) · Italy (1) · Spain (1) · Switzerland (1) · Turkey (Türkiye) (1)
Aaron Farberg, MD (1) · Alper Sindel, DDS, PhD (1) · Busehan Bilgin, DDS (1) · Eben L Rosenthal, MD (1) · Eben Rosenthal, MD (1) · Eldar Rasljanin, DDS (1) · Fred M Baik, MD (1) · Kenji Kobayashi, MD (1) · Lara Dunn, MD (1) · Mehmet Ali Altay, DDS, PhD (1) · Michael Topf, MD (1) · Mike Drake (1) · Rezarta Taga Senirli, MD (1)